Description:
The genetic involvement in the pathogenesis of neurological diseases is profound, with central nervous system disorders accounting for about 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases. Neurological diseases, especially brain diseases, represent the final frontier in medical discovery. Advances in testing, such as next-generation sequencing (NGS), have been instrumental in identifying genetic causes for neurological conditions, driving significant progress in this field.
Kalorama Information’s Genetic Testing Markets for Epilepsy, Autism, Alzheimer’s and Other Neurologic Conditions focuses on the neurological segments of the inherited/genetic disease testing market. This report covers autism, Alzheimer’s disease, and other neurological diseases, highlighting the transformative impact of NGS technologies.
Key Features of the Report:
- Market Overview:
- Comprehensive analysis of the genetic testing market for neurological conditions.
- Examination of market trends, technological advancements, and key drivers.
- Selected Companies and Products:
- Detailed profiles of leading companies and their product offerings in the neurological genetic testing market.
- Market Forecast (2020-2025):
- Genetic neurological testing market projections in dollar values.
- Segmentation by disease type (Autism, Alzheimer’s, and other Neurological Diseases).
- Impact of COVID-19:
- Analysis of how the COVID-19 pandemic has influenced the neurological genetic testing market.
In-Depth Analysis:
- Genetic Testing by Disease Type (2020-2025):
- Autism
- Alzheimer’s Disease
- Other Neurological Diseases
- Next-Generation Sequencing (NGS):
- Overview of NGS capabilities and its role in genetic testing for neurological conditions.
- Insights into the affordability and efficiency of sequencing technologies, including single genes, panels, exomes, and other methods.
Competitive Landscape:
- Companies in the Market:
- Profiles of key players in the genetic testing market for neurological conditions.
- Analysis of their strategies, product innovations, and market positioning.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: Genetic Testing, by Disease Type, 2020-2025 ($ millions)
| Disease Type | 2020 | 2025 | CAGR |
| Autism | $XX Millions | $XX Millions | XX% |
| Alzheimer’s disease | $XX Millions | $XX Millions | XX% |
| Epilepsy | $XX Millions | $XX Millions | XX% |
| Other Neurological diseases (ALS, Parkinson’s, etc) | $XX Millions | $XX Millions | XX% |
| Total | $XX Millions | $XX Millions | XX% |
Source: Kalorama Information
